Good morning :)
Mankind Pharma Ltd

Mankind Pharma Ltd

MANKIND Share Price

NSE
2,414.200.34% (+8.20)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹99,705 cr, stock is ranked 114

Stock is 1.94x as volatile as Nifty

MANKIND Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Avg

Financials growth has been moderate for a few years

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Good

The stock is underpriced and is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

With a market cap of ₹99,705 cr, stock is ranked 114

Stock is 1.94x as volatile as Nifty

MANKIND Performance & Key Metrics

MANKIND Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
52.126.840.04%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
41.316.160.56%

MANKIND Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
88%
Analysts have suggested that investors can buy this stock

from 17 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

MANKIND Company Profile

Mankind Pharma Ltd develops and markets a wide range of pharmaceutical formulations across various therapeutic areas, including anti-infectives and cardiovascular products.

Investor Presentation

View older View older 

May 19, 2026

PDF
View Older Presentations

MANKIND Similar Stocks (Peers)

Compare with peers Compare with peers 

MANKIND Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
38.42
38.42
1Y Return
11.57%
11.57%
Buy Reco %
93.75
93.75
PE Ratio
69.30
69.30
1Y Return
40.01%
40.01%
Buy Reco %
81.48
81.48
PE Ratio
28.15
28.15
1Y Return
8.91%
8.91%
Buy Reco %
62.86
62.86
PE Ratio
21.38
21.38
1Y Return
12.71%
12.71%
Buy Reco %
53.57
53.57
PE Ratio
20.16
20.16
1Y Return
21.73%
21.73%
Buy Reco %
55.56
55.56
Compare with Peers

MANKIND Sentiment Analysis

MANKIND Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

MANKIND Stock Summary · February 2026

Mankind Pharma demonstrated robust growth in Q3 FY26, with an 11.5% year-on-year revenue increase driven by strong performance in chronic therapies and a strategic focus on optimizing its brand portfolio. Despite challenges in the acute therapy segment and concerns over revenue discrepancies, management remains optimistic about sustainable long-term growth, bolstered by improvements in workforce stability and operational efficiency. The company is addressing issues related to primary sales lagging behind secondary sales, while also navigating high net debt levels and the complexities of integrating new personnel into its unique sales culture. As it prepares for future opportunities, particularly in niche markets, Mankind Pharma is committed to enhancing its operational framework to support consistent performance and value creation.

MANKIND Stock Growth Drivers
MANKIND Stock Growth Drivers
7
  • Strong Financial Performance

    Mankind Pharma reported significant revenue growth, with Q3 FY '26 revenue increasing by 11.5% year-on-year

  • Improved Workforce Stability and Team Maturity

    Recent strategic changes have led to significant improvements in workforce stability and team maturity. The

MANKIND Stock Challenges
MANKIND Stock Challenges
6
  • Declining Profitability Metrics

    The company has reported a decrease in adjusted EBITDA margin to 25.9%, down 170 basis

  • Challenges in Revenue Growth

    Despite a reported revenue increase of 11.5% year-on-year, concerns have been raised regarding the growth

MANKIND Forecast

MANKIND Forecasts

Price

Revenue

Earnings

MANKIND

MANKIND

Income

Balance Sheet

Cash Flow

MANKIND Income Statement

MANKIND Income Statement

Loading...

Quarterdec 2023mar 2024jun 2024sep 2024dec 2024mar 2025jun 2025sep 2025dec 2025mar 2026
Total Revenue2,681.682,516.802,975.753,173.063,285.883,333.023,653.403,791.353,643.163,560.21
Operating & Other expensessubtract2,000.451,836.272,196.292,216.612,382.802,400.522,723.582,775.832,754.362,536.21
Depreciation/Amortizationsubtract109.7299.78102.69100.49187.17230.87218.68221.82222.60223.08
Interest & Other Itemssubtract9.199.1710.847.10220.93190.54170.65169.68157.20141.75
Taxes & Other Itemssubtract108.56100.34129.44195.39114.7590.32102.17112.51100.25104.82
EPS11.3311.7613.3916.319.4610.1910.6212.399.9013.44

MANKIND Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2026FY 2026

Annual Report Pending

Investor Presentation

May 19PDF
Feb 3PDF
Nov 6PDF
Jul 31PDF
FY 2025FY 2025

Annual report

PDF

Investor Presentation

May 21PDF
Jan 23PDF
Nov 5PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Aug 2PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

May 30PDF
 

MANKIND Stock Peers

MANKIND Past Performance & Peer Comparison

MANKIND Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Mankind Pharma Ltd52.126.840.04%
Sun Pharmaceutical Industries Ltd38.426.080.87%
Torrent Pharmaceuticals Ltd69.308.530.86%
Cipla Ltd28.153.160.96%

MANKIND Stock Price Comparison

Compare MANKIND with any stock or ETF
Compare MANKIND with any stock or ETF
MANKIND
Loading...

MANKIND Holdings

MANKIND Shareholdings

MANKIND Promoter Holdings Trend

MANKIND Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

MANKIND Institutional Holdings Trend

MANKIND Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has decreased by 1.10%

Tickertape Separator

MANKIND Shareholding Pattern

MANKIND Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding72.66%10.36%4.10%10.24%2.64%

Jun 2025

Sep 2025

Dec 2025

Mar 2026

MANKIND Shareholding History

MANKIND Shareholding History

Dec '24MarJunSepDec '25Mar13.34%12.92%13.07%12.84%11.34%10.24%

Mutual Funds Invested in MANKIND

Mutual Funds Invested in MANKIND

No mutual funds holding trends are available

Top 5 Mutual Funds holding Mankind Pharma Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.9704%1.81%0.15%24/62 (0)
0.8101%1.70%0.95%57/104 (+22)
0.6527%1.72%0.19%23/49 (0)

Compare 3-month MF holding change on Screener

MANKIND Insider Trades & Bulk Stock Deals

MANKIND Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing MANKIND stock

smallcases containing MANKIND stock

A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Mankind Pharma Ltd

Loading...
Pharma Tracker

Pharma Tracker

Created by Windmill Capital

MANKIND's Wtg.
11.24%
11.24%
CAGR
18.47%

MANKIND Events

MANKIND Events

MANKIND Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

MANKIND Dividend Trend

No dividend trend available

MANKIND Upcoming Dividends

MANKIND Upcoming Dividends

No upcoming dividends are available

MANKIND Past Dividends

MANKIND Past Dividends

Cash Dividend

Ex DateEx DateAug 8, 2025

Interim
Interim | Div/Share: ₹1.00

Dividend/Share

1.00

Ex DateEx Date

Aug 8, 2025

MANKIND Stock News & Opinions

MANKIND Stock News & Opinions

Spotlight
Spotlight
Mankind Pharma Ltd eases for fifth straight session

Mankind Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 2412.2, down 0.47% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.11% on the day, quoting at 23888.4. The Sensex is at 75882.34, down 0.17%.Mankind Pharma Ltd has gained around 6.53% in last one month.Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has increased around 6.66% in last one month and is currently quoting at 24659.2, up 0.16% on the day. The volume in the stock stood at 3.04 lakh shares today, compared to the daily average of 7.96 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 2429.3, down 0.46% on the day. Mankind Pharma Ltd tumbled 2.88% in last one year as compared to a 3.49% slide in NIFTY and a 15.46% spurt in the Nifty Pharma index.The PE of the stock is 47.06 based on TTM earnings ending March 26.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Corporate
Mankind Pharma allots 80.872 equity shares under ESOP

Mankind Pharma has allotted 80,872 equity shares under ESOP on 19 May 2026. Consequently, the paid up equity share capital has increased to 41,29,09,200 equity shares having face value of Re 1/- each.

1 month agoCapital Market - Live
Earnings
Earnings
Mankind Pharma consolidated net profit rises 31.75% in the March 2026 quarter

Net profit of Mankind Pharma rose 31.75% to Rs 554.35 crore in the quarter ended March 2026 as against Rs 420.77 crore during the previous quarter ended March 2025. Sales rose 11.81% to Rs 3442.93 crore in the quarter ended March 2026 as against Rs 3079.37 crore during the previous quarter ended March 2025. For the full year,net profit declined 3.92% to Rs 1912.93 crore in the year ended March 2026 as against Rs 1990.96 crore during the previous year ended March 2025. Sales rose 16.96% to Rs 14277.64 crore in the year ended March 2026 as against Rs 12207.44 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales3442.933079.37 12 14277.6412207.44 17 OPM %27.0122.19 -25.3424.72 - PBDT905.41746.30 21 3348.613137.55 7 PBT682.33515.43 32 2462.432516.33 -2 NP554.35420.77 32 1912.931990.96 -4 Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Spotlight
Mankind Pharma Ltd rises for third straight session

Mankind Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 2511.4, up 2% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.4% on the day, quoting at 23783.6. The Sensex is at 75701.49, up 0.4%. Mankind Pharma Ltd has gained around 19.34% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has gained around 9.71% in last one month and is currently quoting at 24551.05, up 0.39% on the day. The volume in the stock stood at 7.22 lakh shares today, compared to the daily average of 5.15 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 2486.3, up 1.66% on the day. Mankind Pharma Ltd is down 2.38% in last one year as compared to a 4.94% slide in NIFTY and a 13.93% slide in the Nifty Pharma index.The PE of the stock is 57.52 based on TTM earnings ending December 25.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Spotlight
Mankind Pharma Ltd up for fifth session

Mankind Pharma Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 2439.2, up 2.69% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.67% on the day, quoting at 24164.3. The Sensex is at 77254.26, down 0.76%. Mankind Pharma Ltd has risen around 18.74% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has risen around 9.02% in last one month and is currently quoting at 24135.5, down 0.02% on the day. The volume in the stock stood at 7.39 lakh shares today, compared to the daily average of 4.54 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 2435.7, up 2.59% on the day. Mankind Pharma Ltd is up 1.29% in last one year as compared to a 0.65% spurt in NIFTY and a 14.52% spurt in the Nifty Pharma index.The PE of the stock is 55.5 based on TTM earnings ending December 25.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Corporate
Mankind Pharma to table results

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 19 May 2026.

1 month agoCapital Market - Live
Spotlight
Spotlight
Mankind Pharma Ltd spurts 1.46%, up for third straight session

Mankind Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 2353.3, up 1.46% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.06% on the day, quoting at 24018.3. The Sensex is at 76839.15, down 0.23%. Mankind Pharma Ltd has added around 15.35% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has added around 10.1% in last one month and is currently quoting at 23568.95, up 2.16% on the day. The volume in the stock stood at 3.9 lakh shares today, compared to the daily average of 4.18 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 2361.1, up 1.34% on the day. Mankind Pharma Ltd is down 3.25% in last one year as compared to a 1.62% fall in NIFTY and a 12.19% fall in the Nifty Pharma index.The PE of the stock is 54.22 based on TTM earnings ending December 25.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Spotlight
Mankind Pharma Ltd gains for fifth session

Mankind Pharma Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 2301.2, up 2.96% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.72% on the day, quoting at 24201.65. The Sensex is at 77776.44, down 0.94%. Mankind Pharma Ltd has added around 15.77% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has added around 3.23% in last one month and is currently quoting at 22455.45, up 2.24% on the day. The volume in the stock stood at 7.66 lakh shares today, compared to the daily average of 5.37 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 2290.5, up 2.77% on the day. Mankind Pharma Ltd is down 11.47% in last one year as compared to a 0.19% fall in NIFTY and a 4.48% fall in the Nifty Pharma index.The PE of the stock is 52.22 based on TTM earnings ending December 25.

1 month agoCapital Market - Live
Spotlight
Spotlight
Mankind Pharma Ltd gains for third straight session

Mankind Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 2188.2, up 2.06% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.72% on the day, quoting at 24539.15. The Sensex is at 79191.47, up 0.85%. Mankind Pharma Ltd has gained around 13.53% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has gained around 1.89% in last one month and is currently quoting at 22456.75, up 0.06% on the day. The volume in the stock stood at 1.76 lakh shares today, compared to the daily average of 5.54 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 2178.8, up 1.87% on the day. Mankind Pharma Ltd is down 15.17% in last one year as compared to a 1.54% jump in NIFTY and a 4.82% jump in the Nifty Pharma index.The PE of the stock is 50.08 based on TTM earnings ending December 25.

2 months agoCapital Market - Live
Corporate
Corporate
Board of Mankind Pharma approves closure of its WoS in Sri Lanka

The board of Mankind Pharma at its meeting held on 13 April 2026 has approved the closure/winding-up of Mankind Pharma Lanka, a wholly owned subsidiary (WOS) company incorporated in Sri Lanka, as due to changed regulatory requirements, the anticipated business objectives are no longer viable. There has been no business operations in the aforesaid WOS, and it is not a material subsidiary of the Company.

2 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Mankind Pharma Ltd (MANKIND) today?

    The share price of MANKIND as on 19th June 2026 is ₹2414.20. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Mankind Pharma Ltd (MANKIND) share?

    The past returns of Mankind Pharma Ltd (MANKIND) share are
    • Past 1 week: -0.20%
    • Past 1 month: -3.59%
    • Past 3 months: 20.66%
    • Past 6 months: 11.15%
    • Past 1 year: 3.83%
    • Past 3 years: 41.97%
    • Past 5 years: 69.74%

  3. What are the peers or stocks similar to Mankind Pharma Ltd (MANKIND)?
  4. What is the dividend yield % of Mankind Pharma Ltd (MANKIND) share?

    The current dividend yield of Mankind Pharma Ltd (MANKIND) is 0.04.

  5. What is the market cap of Mankind Pharma Ltd (MANKIND) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Mankind Pharma Ltd (MANKIND) is ₹99705.49 Cr as of 19th June 2026.

  6. What is the 52 week high and low of Mankind Pharma Ltd (MANKIND) share?

    The 52-week high of Mankind Pharma Ltd (MANKIND) is ₹2716.50 and the 52-week low is ₹1909.70.

  7. What is the PE and PB ratio of Mankind Pharma Ltd (MANKIND) stock?

    The P/E (price-to-earnings) ratio of Mankind Pharma Ltd (MANKIND) is 52.12. The P/B (price-to-book) ratio is 6.84.

  8. Which sector does Mankind Pharma Ltd (MANKIND) belong to?

    Mankind Pharma Ltd (MANKIND) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Mankind Pharma Ltd (MANKIND) shares?

    You can directly buy Mankind Pharma Ltd (MANKIND) shares on Tickertape. Simply sign up, connect your demat account and place your order.